Compare Abbott Laboratories (ABT) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tripadvisor Inc Common Stock — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Tripadvisor Inc Common Stock trades at $13.14 (market cap $1.66B). The key difference: Abbott Laboratories is far larger — about 100.6× Tripadvisor Inc Common Stock's market cap, and Abbott Laboratories pays a 2.63% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| ABT | TRIP | |
|---|---|---|
Market Cap | $166.94B | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $19.14 |
52-Week Low | $82.57 | $9.24 |
Enterprise Value | $193.69B | $1.79B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TRIP trades at $13.72, down 3.99% today, with a consensus price target of $13.87. The stock shows a bullish technical trend and recently announced the $700 million sale of TheFork to American Express. Despite mixed quarterly earnings, 2025 revenue grew to $1.89 billion with a net income margin of 0.99%. Analyst sentiment is mixed, with 60.72% holding and 23.21% recommending buy.
The outlook is cautiously optimistic. The sale of TheFork provides cash but removes a growth segment. Earnings volatility and competitive pressures in online travel pose risks. Upside depends on execution in core segments and macroeconomic stability. Current valuation metrics suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
